# Alderline Group

> Alderline Group is a VC fund backing Medical, Health Care and Life Science. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 4
- Last investment: Feb 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/freepoint-capital-group
- Website: https://freepointcg.com

Alderline Group is a VC fund focused on Medical and Health Care. Freepoint Capital Group focuses on advancing healthcare innovation by investing in enterprises at the intersection of technology, data science, and life sciences. The company aims to enhance clinical efficacy, quality, and accessibility of care through strategic partnerships. With over 70 years of combined experience, Freepoint Capital Groupleverages its extensive network and expertise to drive operational excellence and value creation in the healthcare sector.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 75% |
| Health Care | 3 | 75% |
| Life Science | 2 | 50% |
| Biotechnology | 2 | 50% |
| Pharmaceutical | 2 | 50% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series D | 1 | 25% |
| Series F | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 75% |
| Israel | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Third Arc Bio | Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $52M | Series A | Feb 04, 2026 |  |
| Parabilis Medicines | Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M | Series F | Jan 08, 2026 |  |
| Bright Uro | Bright Uro is an early-stage medical technology company. It is building the next generation of diagnostic devices for Urology. Utilizing advanced hardware, software, and data science can unlock new data streams and offer actionable insight for clinicians. | $32M | Series A | Oct 31, 2024 |  |
| Orasis Pharmaceuticals | Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. | $68M | Series D | Oct 08, 2024 |  |

4 of 4 investments shown.

## Co-investors
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 2 deals together
- [Marshall Wace](https://shizune.co/investors/profile/marshall-wace) — VC Fund, 2 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 2 deals together
- [Aberdeen Investments](https://shizune.co/investors/profile/aberdeen-investments) — VC Fund, 1 deal together
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 1 deal together
- [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Alderline Group invest in?

Alderline Group invests primarily in Medical, Health Care and Life Science startups, most often at Series A and Series D stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alderline Group last invest?

The most recent investment recorded for Alderline Group closed in Feb 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co